© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Medpace Holdings, Inc. (MEDP) stock declined over -0.12%, trading at $620.03 on NASDAQ, down from the previous close of $620.75. The stock opened at $612.24, fluctuating between $612.00 and $622.49 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | 614.15 | 622.49 | 612.00 | 620.03 | 171.17K |
| Aug 21, 2026 | 614.13 | 629.69 | 600.01 | 620.75 | 225.44K |
| Aug 20, 2026 | 597.75 | 627.59 | 597.41 | 612.64 | 248.31K |
| Aug 19, 2026 | 600.00 | 612.11 | 596.22 | 608.27 | 163.28K |
| Aug 18, 2026 | 595.81 | 598.77 | 588.38 | 590.30 | 130.54K |
| Aug 17, 2026 | 578.29 | 597.47 | 571.01 | 597.12 | 162.58K |
| Aug 14, 2026 | 581.95 | 586.28 | 571.74 | 578.50 | 215.63K |
| Aug 13, 2026 | 600.40 | 602.50 | 581.29 | 581.95 | 151.06K |
| Aug 12, 2026 | 598.20 | 604.89 | 593.14 | 596.98 | 310.34K |
| Aug 11, 2026 | 604.32 | 608.18 | 598.22 | 605.50 | 159.91K |
| Aug 10, 2026 | 588.99 | 603.34 | 588.99 | 602.43 | 233.61K |
| Aug 07, 2026 | 590.45 | 594.99 | 582.08 | 590.67 | 136.48K |
| Aug 06, 2026 | 588.00 | 590.00 | 576.72 | 585.01 | 148.64K |
| Aug 05, 2026 | 584.03 | 590.40 | 579.30 | 587.75 | 246.17K |
| Aug 04, 2026 | 577.19 | 577.64 | 563.45 | 575.08 | 227.92K |
| Aug 03, 2026 | 588.07 | 588.07 | 570.34 | 573.29 | 249.53K |
| Jul 31, 2026 | 577.18 | 579.57 | 565.74 | 577.11 | 261.38K |
| Jul 30, 2026 | 577.15 | 586.11 | 565.10 | 578.30 | 318.29K |
| Jul 29, 2026 | 570.85 | 593.29 | 568.31 | 584.93 | 580.87K |
| Jul 28, 2026 | 589.74 | 601.00 | 570.61 | 570.97 | 743.94K |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
| Employees | 6500 |
| Beta | 1.15 |
| Sales or Revenue | $1.89B |
| 5Y Sales Change% | 2.097% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |